Biorem Inc.

Biorem Inc.

3.20
USD
-0.14
(-4.19%)
0.24EPS
8.10P/E
35.39MMarket Cap
Mar 30Next Earn

Total Valuation

USD

As of June 30, 2026, Biorem, Inc. carries a market capitalization of 35.39M, placing it among publicly traded companies globally. Its enterprise value stands at 32.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap35.39M
Enterprise Value32.08M

Important Dates

Biorem, Inc.'s next confirmed earnings release is scheduled for March 30, 2027.

Earnings Date3/30/2027

Share Statistics

As of June 30, 2026, Biorem, Inc. has 16.23M shares outstanding.

Shares Outstanding16.23M

Valuation Ratios

As of June 30, 2026, Biorem, Inc. trades at a trailing price-to-earnings ratio of 8.10. The price-to-sales ratio is 0.99, and the price-to-book ratio stands at 2.86.

PE Ratio8.10
PS Ratio0.99
PB Ratio2.86
P/TBV Ratio2.86
P/FCF Ratio5,941.76
P/OCF Ratio153.37

Enterprise Valuation

As of June 30, 2026, Biorem, Inc. trades at an EV/EBITDA multiple of 5.18 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 5.43 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Biorem, Inc. trades at an EV/FCF ratio of 375.59, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 32.08M versus a market cap of 35.39M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales0.90
EV / EBITDA5.18
EV / EBIT5.43
EV / FCF375.59

Financial Position

As of June 30, 2026, Biorem, Inc. maintains a current ratio of 2.04, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.17, indicating elevated leverage, while an interest coverage ratio of 59.57 demonstrates strong ability to service its debt obligations.

Current Ratio2.04
Quick Ratio1.62
Debt / Equity14.17
Debt / EBITDA0.28
Interest Coverage59.57

Financial Efficiency

Over the twelve months ended June 30, 2026, Biorem, Inc. posted a return on equity (ROE) of 43.58, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 36.46 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 19.82, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 37.05, useful for judging operating efficiency across full business cycles. Inventory turnover of 17.95 indicates how many times Biorem, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)43.58
Return on Assets (ROA)19.82
Return on Invested Capital (ROIC)36.46
Return on Capital Employed (ROCE)37.05
Inventory Turnover17.95

Taxes

USD

Over the twelve months ended June 30, 2026, Biorem, Inc. recorded 1.42M in income tax expense. That works out to an effective tax rate of 24.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 5.80M, leaving 4.38M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax1.42M
Effective Tax Rate24.48

Stock Price Statistics

USD

As of the close on November 16, 2026, Biorem, Inc.'s stock has gained approximately 105.33% over the past 52 weeks. The 50-day moving average sits at 2.50, while the 200-day moving average is 1.97.

52-Week Price Change105.33%
50-Day Moving Average2.50
200-Day Moving Average1.97

Income Statement

USD

Over the twelve months ended June 30, 2026, Biorem, Inc. generated 35.72M in revenue and converted that into 4.38M in net income, yielding earnings per share of 0.24. EBITDA reached 6.20M, while operating income came in at 5.86M.

Revenue35.72M
Gross Profit10.86M
Operating Income5.86M
Pretax Income5.80M
Net Income4.38M
EBITDA6.20M
EBIT5.91M
Earnings Per Share (EPS)0.24

Balance Sheet

USD

As of June 30, 2026, Biorem, Inc. holds 5.06M in cash and equivalents against 1.76M in total debt, resulting in a net debt position of -3.96M. Total book value stands at 12.39M, with working capital of 11.86M providing operational flexibility.

Cash & Cash Equivalents5.06M
Total Debt1.76M
Net Debt-3.96M
Equity (Book Value)12.39M
Book Value Per Share0.76
Working Capital11.86M

Cash Flow

USD

Biorem, Inc. produced 231,419.59 in operating cash flow over the twelve months ended June 30, 2026. After subtracting -224,598.90 in capital expenditures, free cash flow totaled 6,820.70 - equivalent to 0.00 per share.

Operating Cash Flow231,419.59
Capital Expenditures-224,598.90
Free Cash Flow6,820.70

Margins

Over the twelve months ended June 30, 2026, Biorem, Inc. posted a gross margin of 30.40, reflecting its pricing power and cost economics. The operating margin of 16.41 and net profit margin of 12.26 provide insight into operational efficiency.

Gross Margin30.40
Operating Margin16.41
Pretax Margin16.24
Profit Margin12.26
EBITDA Margin17.35

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.02, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.43, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Biorem, Inc. shareholders.

Shareholder Yield1.43
FCF Yield0.02

Stock Splits

Biorem, Inc.'s most recent stock split took place on January 21, 2005 with a 4:1 split ratio.

Last Split Date1/21/2005
Split Ratio4:1

Scores

As of June 30, 2026, Biorem, Inc. has an Altman Z-Score of 4.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.74